NCT00350272 - Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

April 30, 2009

Conditions

HIV Infections

Interventions

DRUG

Elvucitabine

Elvucitabine 10 mg orally daily

DRUG

Lamivudine

Lamivudine 300 mg orally daily

DRUG

Tenofovir

Tenofovir open-label 300 mg orally daily

DRUG

Efavirenz

Efavirenze open-label 600 mg orally daily

Trial Locations (26)

10003

Clinical Trial Site, New York

20007

Clinical Trial Site, Washington D.C.

Clinical Trial Site, Washington D.C

23666

Clinical Trial Site, Hampton

32803

Clinical Trial Site, Orlando

33133

Clinical Trial Site, Miami

33136

Clinical Trial Site, Miami

33401

Clinical Trial Site, West Palm Beach

33602

Clinical Trial Site, Tampa

33614

Clinical Trial Site, Tampa

33765

Clinical Trial Site, Clearwater

33901

Clinical Trial Site, Fort Myers

60611

Clinical Trial Site, Chicago

67214

Clinical Trial Site, Wichita

72207

Clinical Trial Site, Little Rock

75204

Clinical Trial Site, Dallas

75705

Clinical Trial Site, Austin

77004

Clinical Trial Site, Houston

77009

Clinical Trial Site, Houston

77030

Clinical Trial Site, Houston

77098

Clinical Trial Site, Houston

90069

Clinical Trial Site, Los Angeles

90813

Clinical Trial Site, Long Beach

02215

Clinical Trial Site, Boston

07102

Clinical Trial Site, Newark

00909

Clinical Trial Site, San Juan